Zac McDonald1, Signy Chow2,4, Kathleen Gorospe1, Xin Xu1, Paul Taylor1, Qixin Liu1, Zhihua Li2, Ziwei Han5, Trevor J. Pugh2,3, Suzanne Trudel2, Bin Ma5
1Rapid Novor Inc., Kitchener, ON, Canada
2Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
3Ontario Institute for Cancer Research, Toronto, ON, Canada
4Sunnybrook Health Sciences Centre, Toronto, ON, Canada
5University of Waterloo, ON, Canada

Abstract

The DNA sequences of antibodies are highly diverse due to the V-(D)-J recombination and hypersomatic mutations. As such, relying on homology-based searches to sequence novel antibodies can introduce bias to sequences obtained from proteomics approaches. De novo sequencing of antibody proteins directly from MS data is an improvement over the conventional database approach, but recent de novo sequencing studies are based on very few antibodies that may not be representative of samples. Here, we conduct the first large scale test of the REmAb® sequencing platform by comparing its protein and DNA sequencing results of 24 myeloma cell lines.

Key Takeaways

  • REmAb® de novo protein sequencing is capable of fully sequencing antibodies comparably to DNA sequencing
  • REmAb® could fill in the gaps of sequences accurately even in cases where DNA sequencing could not

Download the Full Case Study

Whitepaper: Prevalence of Secondary Light Chains

Talk to Our Scientists.

We Have Sequenced 3000+ Antibodies and We Are Eager to Help You.

Through next generation protein sequencing, Rapid Novor enables reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and developed the first recombinant polyclonal antibody diagnostics.

Talk to Our Scientists.

We Have Sequenced 3000+ Antibodies and We Are Eager to Help You.

Through next generation protein sequencing, Rapid Novor enables timely and reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and ran the first recombinant polyclonal antibody diagnostics

Talk to our scientists. We have sequenced over 3000 antibodies and we are eager to help you.